Allergen immunotherapy / Stallergenes - LARVOL DELTA

Consistency of treatment efficacy across main comorbidity subgroups in pediatric birch-induced allergic rhinoconjunctivitis in the YOBI trial (EAACI 2026) - "The YOBI randomized, double‑blind, placebo‑controlled phase III trial investigated, through pre-specified subgroup analyses, whether these comorbidities modify the efficacy of 300 IR birch liquid sublingual immunotherapy (SLIT‑liquid) in children and adolescents with moderate‑to‑severe birch‑induced ARC...In the subgroup analyses no significant treatment‑by‑asthma or treatment‑by‑OAS interaction was detected (interaction p=0.753 and p=0.231, respectively) (Table). Conclusion In this large pediatric RCT, 300IR birch SLIT-liquid provided consistent, clinically relevant improvement in ARC symptoms across major comorbidity subgroups, supporting its use in children and adolescents with birch-induced ARC irrespective of concomitant asthma or OAS."

Clinical • Allergy • Immunology

Sustained effectiveness of the 300 IR house dust mite sublingual tablet over 2 treatment years in a real-world data setting – results of a non-interventional study (EAACI 2026) - "Background The real-world, non-interventional VORAN study demonstrated the effectiveness of the 300 IR house dust mite (HDM) sublingual immunotherapy (SLIT) tablet in HDM-induced allergic rhinoconjunctivitis (ARC) during the first treatment year (Y1) 1...Conclusion In this real-world setting, the 300 IR HDM SLIT tablet progressively reduced the severity of allergic symptoms and ARC symptomatic medication use, and improved sleep over a two-year treatment period. Robust early improvements, evident within the first three months and consolidated during Y1, were sustained through Y2, suggesting the potential for continued benefit in Y3."

Clinical • Observational data • Real-world • Real-world evidence • Immunology

Potential for clinical remission in birch pollen-induced allergic rhinoconjunctivitis with a 300IR birch liquid sublingual immunotherapy (EAACI 2026) - P3 | "Front. Allergy 2025; 5:1531788"

Clinical • Late-breaking abstract • Allergy • Immunology • Inflammation

Potential for clinical remission in house dust mite allergic rhinitis with the 300IR house dust mite sublingual immunotherapy tablet (EAACI 2026) - P3 | "Front. Allergy 2025; 5:1531788"

Clinical • Late-breaking abstract • Allergic Rhinitis • Immunology • Inflammation

Quality of Life Improvement with 300 IR Liquid Sublingual Immunotherapy in Allergic Rhinitis: A Systematic Review and Meta-analysis of Randomised and Non-randomised Studies (EAACI 2026) - "Conclusion This is the first meta-analysis assessing QoL outcomes in non-randomised SLIT studies, offering complementary real-world data and more product-specific evidence. Treatment of AR with 300 IR SLIT-liquid was associated with clinically meaningful QoL improvements, with an impact observed as soon as the first year of treatment, regardless of the considered allergen and asthma status."

HEOR • Late-breaking abstract • Retrospective data • Review • Allergic Rhinitis • Immunology • Inflammation

Reduction in healthcare resource utilization in pediatric patients treated with 300 IR liquid SLIT: a real‑world subanalysis from Spain and Italy (EAACI 2026) - "Background Sublingual immunotherapy (SLIT) is an effective, disease‑modifying treatment for pediatric respiratory allergies and may reduce healthcare costs by decreasing symptoms and healthcare resource utilization (HCRU)...Conclusion In this pediatric real‑world subanalysis from Spain and Italy, treatment with 300 IR liquid SLIT was associated with a clinically relevant and statistically significant reduction in symptomatic medication use and healthcare visits, including ED and GP consultations. These findings highlight the value of SLIT not only for symptom control but also for decreasing direct healthcare resource utilization in children and adolescents with allergic rhinitis, a population with high long‑term disease burden and substantial potential for early, cost‑saving intervention."

Clinical • HEOR • Real-world • Real-world evidence • Allergic Rhinitis • Immunology • Inflammation

Impact of liquid sublingual immunotherapy on sleep and mental health issues in patients with allergic rhinitis with or without asthma in the real-world EfficAPSI study (EAACI 2026) - "Moreover, the risk of anxiety and depression diminished by one half and one third, respectively. Altogether, the results suggest that beyond effectiveness, this treatment has the potential to improve the quality of life of AR patients."

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Allergic Rhinitis • Immunology • Inflammation

Efficacy and Safety of 300 IR Liquid Sublingual Immunotherapy in Allergic Asthma: A Systematic Review and Meta-analysis of Randomised Controlled Trials (EAACI 2026) - "The low heterogeneity for medication score and FEV₁ suggests that focusing on a single SLIT formulation may provide more homogeneous and robust estimates of efficacy. Further well-designed trials may refine effect size estimates and better characterise patient-level determinants of response."

Late-breaking abstract • Retrospective data • Review • Immunology

Treatment effect of 300IR birch liquid sublingual immunotherapy translated into clinically meaningful benefits for the patient: results of the YOBI trial (EAACI 2026) - "Similarly, assuming that the observed reduction of 2.62-point in the TCS 0-38 over BPS2 is applied entirely to the symptom of nasal obstruction, and all other symptoms and medication use remain unchanged, this would result in a shift from 62% of days with severe symptoms and 38% of days with mild symptoms in a placebo patient to a complete absence of symptoms in a SLIT-treated patient (figure: BPS2 illustration #1). Conclusion These patient-centred examples suggest that 300 IR birch pollen SLIT-liquid can translate into substantial reductions in symptom burden and medication use in paediatric patients with birch-induced ARC."

Clinical • Late-breaking abstract • Immunology

Safety of a 300IR daily SLIT-liquid in patients 5-17 years old with birch pollen allergic rhinoconjunctivitis: results of the YOBI trial (EAACI 2026) - "Background 300IR birch liquid sublingual immunotherapy (SLIT-liquid) has demonstrated sustained clinical efficacy and safety for two consecutive pollen seasons in adults with birch pollen-induced allergic rhinoconjunctivitis (ARC) with/without asthma...No SUSARs or fatal outcomes were reported during the trial. Conclusion Consistent with the established safety profile of 300IR birch SLIT-liquid, treatment-related adverse events in pediatric patients were mild to moderate, and no new safety signals were identified over the 2 BPS."

Clinical • Allergy • Immunology

Challenges of using clinical scores as primary endpoints in allergology trials (EAACI 2026) - "Background Composite clinical scores are widely used to assess the efficacy of allergen immunotherapy (AIT) in allergic rhinoconjunctivitis...Conclusion The CSMS exhibits structural and inferential limitations that challenge its suitability as a primary continuous endpoint in allergology trials. The adoption of other clinically meaningful outcomes such as responder-based endpoints, together with appropriate statistical frameworks, may substantially improve the robustness and interpretability of AIT clinical trial outcomes."

Clinical • Immunology

Pollen-Food Allergy Syndrome (PFAS): A New Paradigm in Allergy Practice – Results of a Survey Among Allergists (EAACI 2026) - "To explore the perceptions of French-speaking allergists regarding the frequency, evolution, and management of Pollen-Food Allergy Syndrome, as well as the role of Allergen Immunotherapy...Conclusion PFAS is no longer a simple secondary symptom; it has emerged as a major clinical marker influencing quality of life and therapeutic strategies for pollen-allergic patients. The increasing frequency and severity confirmed by allergists highlight the urgent need to integrate this phenomenon into clinical practice, particularly within the context of climate change and the diversification of allergens"

IO biomarker • Allergic Rhinitis • Allergy • Food Hypersensitivity • Immunology • Inflammation

Effectiveness of the 300IR house dust mite sublingual tablet according to the patients' sensitisation and allergy profile in the real-world, non-interventional VORAN study (EAACI 2026) - "PS/PA patients took slightly more symptomatic ARC medication (mainly antihistamines) than MS/MA...More than 90% of patients assessed their well-being as much better or somewhat better. Conclusion In this large real-world study, the 300IR HDM SLIT-tablet effectively reduced allergic symptoms and symptomatic medication use and improved sleep in adults and adolescents in all subgroups."

Clinical • Real-world • Real-world evidence • Allergy • Immunology

Efficacy and safety of a 300IR daily dose of a SLIT of birch pollen allergen extract in children and adolescents with allergic rhinoconjunctivitis: results from the YOBI trial (EAACI 2026) - "Background Sublingual immunotherapy (SLIT) is a guideline-recommended treatment for allergic rhinoconjunctivitis (ARC), reducing symptoms and medication use...Consistent with the established safety profile of 300IR birch SLIT-liquid, treatment-related adverse events were mild to moderate, and no new safety signals were identified. Conclusion 300IR birch SLIT-liquid demonstrated a clinically relevant and highly statistically significant improvement of birch-induced ARC (with/without asthma) in paediatric population during BPS1 and BPS2, confirming a sustained effect, while showing a consistent safety profile."

Clinical • Immunology

Effectiveness of the 300IR house dust mite sublingual tablet in the real-world, non-interventional VORAN study: a responder analysis (EAACI 2026) - "HR took slightly more symptomatic ARC medication (mainly nasal corticosteroids) than LR...The safety and tolerability were good in both subgroups. Conclusion This study confirmed the effectiveness of 300IR HDM SLIT-tablet in HDM ARC patients, especially in those with more frequent and severe symptoms, and more pronounced impact of HDM on sleep at baseline."

Clinical • Real-world • Real-world evidence • Immunology

Expanding grass pollen allergomes to improve molecular characterization of diagnostic and allergen immunotherapy products (EAACI 2026) - "The expanded allergome information substantially increased the molecular resolution achieved in the characterization of diagnostic and AIT products. Conclusion Proteomics informed by transcriptomics enables a comprehensive expansion of grass pollen allergomes and provides significant added value for the molecular profiling of diagnostic and AIT products."

Allergy • Immunology

Efficacy of a 300IR birch liquid sublingual immunotherapy during the alder and hazel pollen seasons: results of the YOBI trial (EAACI 2026) - "The results during alder and hazel PSs mirrored the positive results observed during the birch PS (Table). Conclusion 300IR birch SLIT-liquid demonstrated statistically significant reductions in the TCS 0-38 during both the alder/hazel and birch seasons, suggesting that it may improve ARC symptoms and reduce rescue medication use across the broader tree PS."

Clinical • Immunology

Consistent efficacy of a seasonal 300IR birch pollen sublingual immunotherapy in children and adolescents during worst pollen exposure: results of the YOBI trial (EAACI 2026) - "Consistent improvements were observed for CSMS 0-6 , DSS 0-18 and DMS 0-20 (p<0.0001). Conclusion 300IR birch SLIT-liquid demonstrated consistent and robust clinical efficacy in paediatric patients with birch-induced ARC during 2 consecutive BPSs, in particular during the worst BPS periods."

Clinical • Immunology

Efficacy of 300IR birch pollen liquid sublingual immunotherapy in paediatric patients with birch allergic rhinoconjunctivitis in relation to disease activity: results from the YOBI clinical trial (EAACI 2026) - "Conclusion In this large RCT, 300IR birch SLIT-liquid demonstrated clinically relevant and highly statistically significant efficacy in the overall population of children and adolescents with birch ARC, with the greatest improvements observed in the tertile wherein patients reflected a higher disease activity. Together, these results suggest efficacy is maintained, and may be greater in patients with higher disease activity, supporting benefits in all situations, especially where patients are most affected."

Clinical • Allergy • Immunology

Reduced risk of respiratory infections with liquid sublingual immunotherapy in patients with allergic rhinitis with or without asthma in the real-world EfficAPSI study (EAACI 2026) - "1.Demoly et al. Lancet Regional Health-Europe 2024; 41:100915"

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Allergic Rhinitis • Immunology • Inflammation

Pragmatic Strategies for Reducing Variability and Risk in Food Oral Immunotherapy. (PubMed, Clin Rev Allergy Immunol) - "Precise dosing, consistent procedures, neutral vehicles, and validated allergen quantification tools could potentially ensure reproducibility, reduce risk, strengthen clinical effectiveness, and facilitate meaningful comparisons across clinical trials and research studies. We suggest that standardized "pharmaceutical grade" products, while not always a practical option, should be preferred when available."

Journal • Review • Allergy • Food Hypersensitivity • Immunology

Biphasic Effects on Allergen-Specific Type 2 Memory B Cells Over 18 Months Sublingual Immunotherapy for House Dust Mite Allergy. (PubMed, Allergy) - "A biphasic Bmem response with early phenotypic changes followed by loss of the Type 2 state was observed during 18 months of AIT. As durable unresponsiveness takes 18 months of AIT, deletion of Type 2 Bmem is likely an important step in disease attenuation. Interventions that expedite this outcome may be beneficial in driving remission."

Journal • Allergic Rhinitis • Allergy • Asthma • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases • ITGB1

Allergic rhinitis activity and efficacy of 300 IR house dust mite sublingual immunotherapy tablet in pediatrics. (PubMed, Pediatr Allergy Immunol) - "The greatest improvements occurred in the tertile where pediatric patients exhibited higher disease activity. This underscores the true efficacy of 300 IR HDM SLIT-tablet during periods when patients experience the most troublesome symptoms."

Journal • Allergic Rhinitis • Immunology • Inflammation • Pediatrics

Expanding Grass Pollen Allergomes: Added Value for Allergen Product Profiling (AAAAI 2026) - "The goal of this study was to broaden the known pollen allergomes of sweet vernal, orchard, perennial rye and kentucky bluegrass using a proteomics informed by transcriptomics approach with the objective to improve allergen immunotherapy (AIT) product characterization...In-depth proteomics informed by transcriptomics has supported characterization of AIT products confirming the added value of the extended grass pollen allergomes. Conclusions Proteomics informed by transcriptomics is a useful approach to deepen allergome knowledge of allergenic materials with the objective of better characterizing patient exposure and AIT products."

Impact of Liquid Sublingual Immunotherapy on Health Care Resource Use in Allergic Rhinitis and Asthma in the Real-world EfficAPSI Study. (PubMed, J Investig Allergol Clin Immunol) - "In this national real-world study involving the largest number of person-years followed in the field of AIT to date, SLIT-liquid was associated with a reduction in AR and dispensation of asthma medication, including systemic corticosteroids, and medical consultations. The results recorded in the last 2 post-treatment FUPs suggest a sustained effect of SLIT-liquid."

Journal • Real-world evidence • Allergic Rhinitis • Asthma • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases